Neural Circuit Mechanism of Inflammatory Bowel Disease Combined With Depression

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-65
SponsorLanZhou University

About this trial

The goal of this observational study is to understand the effects of gut microbiota dysbiosis treatment in patients with inflammatory bowel disease (IBD) combined with depression. The main question it aims to answer is:

Does fecal microbiota transplantation (FMT) improve depression symptoms in IBD patients by altering GABA levels in the medial prefrontal cortex?

Participants already undergoing fecal microbiota transplantation (FMT) as part of their regular medical care for IBD and comorbid depression will undergo regular assessments of GABA levels, gut microbiota, and depression symptoms for the duration of the study.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial population

The inflammatory bowel disease (IBD) combined with depression have increased psychological stress. Individuals with IBD often face prolonged physical discomfort and treatment challenges, which can lead to increased emotional burden and susceptibility to depression. IBD is a chronic condition requiring long-term management and treatment. These ongoing lifestyle changes and medical burdens may contribute to feelings of sadness and depression. In summary, depression is common among individuals with inflammatory bowel disease. It is important to monitor the mental health of patients during treatment and provide proactive psychological support and intervention when needed.

Trial design

Design model

Case-control

Time perspective

Cross-sectional

Treatments tested in this trial

  • Magnetic resonance imaging scanning

    Radiation

    Perform brain diffusion imaging, magnetic resonance spectroscopy, and functional magnetic resonance imaging scans on all individuals

  • FMT Protocol

    Drug

    Treatment of disease groups (UC and CD) using prepared fecal microbiota transplantation solution

Treatment groups

100 Participants
are divided into 3 treatment groups
Group A: CD2 interventions
Group B: UC2 interventions
Group C: HC1 intervention

Trial outcomes

Primary outcomes

1

Magnetic resonance spectroscopy

Changes in GABA content in the prefrontal lobe of the brain

Time frame
1 week before and 1 week after FMT
2

Magnetic resonance spectroscopy

Changes in alpha diversity and differential abundance of gut microbiota

Time frame
1 week before and 1 week after FMT

Secondary outcomes

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: